Teladoc Health, Inc. (TDOC)
USD 9.46
(-6.06%)
USD 9.46
(-6.06%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.6 Billion USD | 8.13% |
| 2022 | 2.4 Billion USD | 18.41% |
| 2021 | 2.03 Billion USD | 85.81% |
| 2020 | 1.09 Billion USD | 97.71% |
| 2019 | 553.3 Million USD | 32.4% |
| 2018 | 417.9 Million USD | 79.14% |
| 2017 | 233.27 Million USD | 89.42% |
| 2016 | 123.15 Million USD | 59.15% |
| 2015 | 77.38 Million USD | 77.78% |
| 2014 | 43.52 Million USD | 118.67% |
| 2013 | 19.9 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 642.44 Million USD | -0.57% |
| 2024 Q1 | 646.13 Million USD | -2.18% |
| 2024 Q3 | 640.5 Million USD | -0.3% |
| 2023 Q1 | 629.24 Million USD | -1.33% |
| 2023 Q3 | 660.23 Million USD | 1.2% |
| 2023 Q4 | 660.52 Million USD | 0.04% |
| 2023 FY | 2.6 Billion USD | 8.13% |
| 2023 Q2 | 652.4 Million USD | 3.68% |
| 2022 FY | 2.4 Billion USD | 18.41% |
| 2022 Q4 | 637.7 Million USD | 4.3% |
| 2022 Q1 | 565.35 Million USD | 2.01% |
| 2022 Q2 | 592.37 Million USD | 4.78% |
| 2022 Q3 | 611.4 Million USD | 3.21% |
| 2021 FY | 2.03 Billion USD | 85.81% |
| 2021 Q4 | 554.23 Million USD | 6.24% |
| 2021 Q3 | 521.65 Million USD | 3.68% |
| 2021 Q1 | 453.67 Million USD | 18.35% |
| 2021 Q2 | 503.13 Million USD | 10.9% |
| 2020 Q4 | 383.32 Million USD | 32.72% |
| 2020 Q3 | 288.81 Million USD | 19.82% |
| 2020 FY | 1.09 Billion USD | 97.71% |
| 2020 Q1 | 180.79 Million USD | 15.53% |
| 2020 Q2 | 241.03 Million USD | 33.31% |
| 2019 Q1 | 128.57 Million USD | 4.75% |
| 2019 Q3 | 137.96 Million USD | 5.91% |
| 2019 Q2 | 130.27 Million USD | 1.32% |
| 2019 Q4 | 156.48 Million USD | 13.42% |
| 2019 FY | 553.3 Million USD | 32.4% |
| 2018 Q3 | 110.96 Million USD | 17.35% |
| 2018 Q1 | 89.64 Million USD | 16.21% |
| 2018 FY | 417.9 Million USD | 79.14% |
| 2018 Q4 | 122.74 Million USD | 10.62% |
| 2018 Q2 | 94.56 Million USD | 5.48% |
| 2017 Q4 | 77.14 Million USD | 12.37% |
| 2017 FY | 233.27 Million USD | 89.42% |
| 2017 Q3 | 68.65 Million USD | 53.95% |
| 2017 Q2 | 44.59 Million USD | 3.95% |
| 2017 Q1 | 42.89 Million USD | 14.7% |
| 2016 Q2 | 26.48 Million USD | -1.49% |
| 2016 Q1 | 26.88 Million USD | 18.77% |
| 2016 Q4 | 37.4 Million USD | 15.5% |
| 2016 FY | 123.15 Million USD | 59.15% |
| 2016 Q3 | 32.38 Million USD | 22.25% |
| 2015 Q1 | 16.48 Million USD | 27.55% |
| 2015 FY | 77.38 Million USD | 77.78% |
| 2015 Q4 | 22.63 Million USD | 13.35% |
| 2015 Q3 | 19.97 Million USD | 9.24% |
| 2015 Q2 | 18.28 Million USD | 10.89% |
| 2014 Q1 | 9.4 Million USD | 0.0% |
| 2014 Q3 | 10.9 Million USD | 5.99% |
| 2014 Q4 | 12.92 Million USD | 18.54% |
| 2014 Q2 | 10.28 Million USD | 9.38% |
| 2014 FY | 43.52 Million USD | 118.67% |
| 2013 FY | 19.9 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| American Well Corporation | 259.04 Million USD | -904.611% |
| Doximity, Inc. | 475.42 Million USD | -447.391% |
| Evolent Health, Inc. | 1.96 Billion USD | -32.513% |
| MultiPlan Corporation | 961.52 Million USD | -170.655% |
| Phreesia, Inc. | 356.29 Million USD | -630.402% |
| Veeva Systems Inc. | 2.36 Billion USD | -10.1% |